Naples

• This study has 2 phases: a Phase 1b evaluation of elacestrant in combination with abemaciclib followed by a Phase 2 evaluation of elacestran … Recruiting
  2024-512878-98-00 9 2023-05-16 Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breas
• A Long-term Study in Children and Teenagers with Ulcerative Colitis or Crohn’s Disease treated with Vedolizumab IV Recruiting
  2023-509046-36-00 5 2023-04-26 Active Ulcerative Colitis (UC) or Crohn's disease (CD)
• A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF Class 1 and Class 2 alterations, in participan … Recruiting
  2024-513578-23-00 4 2023-03-21 Tumors harboring BRAF alterations
• An open-label, dose-escalation, dose-finding, and proof-of-concept trial of SP-420 in subjects with transfusion-dependent α- or β-thalassemi … Recruiting
  2023-507396-21-00 4 2023-03-16 transfusion-dependent α- or β-thalassemia or low-risk myelodysplastic
• Phase 2 trial of Translational approach to first line cHemoimmunotherapy followed by maintenance with pembrOlizumab and olaparib in Extensiv … Recruiting
  2024-514666-39-00 4 2023-03-16 Extensive-Stage Small-Cell Lung Cancer (ES SCLC)
• phase I/II b study of atezolizumab and BEGEV as first salvage treatment in patients with relapsed or refractory Hodgkin’s lymphoma candidate … Recruiting
  2024-511631-10-00 9 2023-02-27 Hodgkin’s lymphoma
• Efficacy and safety of the combination of Cisplatin plus Nab-paclitaxel and Nivolumab with radiotherapy after maximal tumor resection in non … Recruiting
  2024-518937-26-00 4 2023-02-21 Patients with non-metastatic muscle invasive bladder cancer
• Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN). Recruiting
  2023-507233-19-00 10 2023-02-16 Treatment of IgAN
• A multi-center phase 3 study of 18F-florbetaben positron emission tomography/computed tomography (PET-CT) to non-invasively diagnose cardiac … Recruiting
  2024-517942-33-03 5 2023-02-04 cardiac amyloidosis
• A Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cut … Recruiting
  2023-505634-94-00 10 2023-02-02 Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythe
• Phase 2 Study of Luspatercept in Adults and Adolescents with Alpha (α)-thalassemia Recruiting
  2022-502328-35-00 4 2023-01-30 Alpha (α)-thalassemia
• A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid … Recruiting
  2023-505065-91-00 4 2023-01-30 Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small C
• VEMURAFENIB PLUS RITUXIMAB AS A CHEMOTHERAPY-FREE ALTERNATIVE TO CLADRIBINE FOLLOWED BY MRD-GUIDED RITUXIMAB IN FRONT-LINE HAIRY CELL LEUKEM … Recruiting
  2024-520119-41-00 4 2023-01-15 Previously untreated patients with diagnosis of HCL
• International multicenter, open-label clinical trial for the treatment of acute myeloid leukemia in children and adolescents Recruiting
  2022-500783-35-00 5 2022-12-06 Acute Myeloid Leukemia
• Clinical study to test the safety, tolerance and preliminary efficacy of oral ITF3756 administered alone or in combination with an anti-prot … Recruiting
  2022-501089-22-00 1 2022-11-29 Advanced solid tumors
• A study of tucatinib with trastuzumab and mFOLFOX6 versus standard of care treatment in first-line HER2+ metastatic colorectal cancer Recruiting
  2024-514180-25-00 5 2022-11-21 unresectable or metastatic HER2+ colorectal cancer
• Efficacy and Safety Study of Nipocalimab for Adults with CIDP Recruiting
  2023-508425-28-00 4 2022-10-24 Chronic Inflammatory Demyelinating Polyneuropathy
• A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination … Recruiting
  2023-503442-30-00 5 2022-10-14 Multiple Myeloma
• The study's aim is to treat adult patients affected by Ph-like ALL, a Philadelphianegative ALL subtype, with a combination of the tyrosine k … Recruiting
  2023-510240-20-00 4 2022-10-05 Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.
• Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Dia … Recruiting
  2023-510384-36-00 5 2022-09-13 Newly Diagnosed Multiple Myeloma
• A study to Investigate the efficacy and safety of Depemokimab compared with placebo in Adults with Hypereosinophilic Syndrome (HES) Recruiting
  2023-510346-25-00 5 2022-09-01 Hypereosinophilic Syndrome (HES)
• Asciminib Roll-over Study Recruiting
  2023-507557-16-00 5 2022-08-31 chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive
• A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-C … Recruiting
  2022-502646-27-00 10 2022-06-24 Relapsed or Refractory Diffuse Large B-Cell Lymphoma
• A clinical study to learn about the safety and effects of KIN-2787, a new oral anticancer drug for the treatment of patients with BRAF and/o … Recruiting
  2024-516331-27-00 3 2022-06-10 Participants with BRAF and/or NRAS mutation positive tumors

Showing 529–552 of 1,177 trials